查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1590817

泌尿生殖药物市场：按产品、适应症、药物类型 - 全球预测 2025-2030

Genitourinary Drugs Market by Product (Anti-infectives, Gynecological, Hormonal Therapy), Indication (Benign Prostatic Hyperplasia, Bladder Cancer, Cervical Cancer), Drug Type - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年泌尿生殖药物市场价值为383亿美元，预计2024年将达到398.3亿美元，复合年增长率为4.17%，到2030年将达到510.1亿美元。

泌尿生殖药物市场主要涉及用于治疗影响生殖和泌尿器官系统的疾病的药物。这包括治疗尿道感染、勃起功能障碍、尿失禁、膀胱过动症和其他相关病症的药物。由于老化和生活方式改变等因素，泌尿器官系统疾病的盛行率日益增加，支持了对该市场的需求。这些疗法的应用涵盖各种医疗保健环境，包括医院、诊所和居家照护，目标最终使用者是需要急性和慢性治疗解决方案的患者。关键的成长要素包括生物技术和药物的进步，促进更有效和更有针对性的治疗方法的开发，诊断工具的改进，加强早期检测，以及医疗保健成本的上升。

主要市场统计
基准年[2023] 383亿美元
预测年份 [2024] 398.3亿美元
预测年份 [2030] 510.1亿美元
复合年增长率（%） 4.17%

最近的市场机会来自越来越多地采用具有更高治疗效率和更少副作用的个人化医疗和生技药品。透过利用这些，公司可以专注于开发适合个别患者基因特征的药物。另一个有前景的领域是数位治疗，它透过整合增强患者依从性和监测的技术来改善治疗结果。阻碍市场扩张的挑战包括严格的监管核准减缓新药的推出、研发成本上升以及导致学名药竞争的专利到期。随着医疗保健系统努力控製成本，定价压力和报销问题进一步限制了市场。

创新的重点是探索新的药物输送系统，例如奈米颗粒和缓释性，这些系统可以解决患者的依从性并提高药物疗效。此外，针对罕见泌尿系统疾病的未满足需求可能会提供利基市场成长机会。在持续的研发努力的推动下，市场的本质是竞争激烈且快速发展。策略伙伴关係和研究合作可以提供一种整合资源并加速开发新药的方法。总之，为了确保泌尿生殖药物市场的持续成长和竞争优势，保持对研发的明确关注、适应监管更新并应对技术进步非常重要。

市场动态：快速发展的泌尿生殖药物市场的关键市场洞察

供需的动态交互作用正在改变泌尿生殖医学市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 泌尿生殖系统疾病盛行率增加
    • 管道药物增加
    • 人们越来越担心尿失禁和阳痿
  • 市场限制因素
    • 市面上有仿冒品和学名药
  • 市场机会
    • 製药公司的联合研发倡议
    • 扩大医疗保健投资以改善治疗
  • 市场挑战
    • 缺乏用药依从性
    • 专利到期

波特的五力策略工具驾驭泌尿生殖药物市场

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解泌尿生殖药物市场的外部影响

外部宏观环境因素在塑造泌尿生殖药物市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解泌尿生殖医学市场的竞争状况

对泌尿生殖药物市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵泌尿生殖药物市场供应商的绩效评估

FPNV定位矩阵是评估泌尿生殖药物市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘泌尿生殖药物市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，对泌尿生殖药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 泌尿生殖系统疾病盛行率增加
      • 管道药物增加
      • 人们越来越关注尿失禁和阳痿
    • 抑制因素
      • 市面上有假药和学名药
    • 机会
      • 製药公司的联合研发倡议
      • 增加医疗保健投资以改善治疗
    • 任务
      • 缺乏合规性
      • 专利持续到期
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章泌尿生殖药物市场：副产品

  • 抗感染
  • 妇科
  • 荷尔蒙疗法
  • 泌尿系统

第七章依适应症分列的泌尿生殖药物市场

  • 良性摄护腺增生
  • 膀胱癌
  • 子宫颈癌
  • 勃起功能障碍
  • 血尿
  • 间质性膀胱炎
  • 卵巢癌
  • 摄护腺癌
  • 肾癌
  • 性行为感染传染病
  • 尿失禁和膀胱过动症
  • 尿道感染

第八章按药物类型分類的泌尿生殖药物市场

  • 荷尔蒙疗法
  • 阳痿药物
  • 尿路解痉药
  • 尿液pH调节剂
  • 子宫鬆弛剂
  • 子宫兴奋剂

第9章：美洲泌尿生殖药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太泌尿生殖药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲/中东/非洲泌尿生殖医学市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • AbbVie Inc.
  • Asieris Pharmaceuticals
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Cipla Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • The Bristol Myers Squibb Company
Product Code: MRR-ED54C46E88A6

The Genitourinary Drugs Market was valued at USD 38.30 billion in 2023, expected to reach USD 39.83 billion in 2024, and is projected to grow at a CAGR of 4.17%, to USD 51.01 billion by 2030.

The genitourinary drugs market is primarily concerned with medications used to treat disorders affecting the genital and urinary systems. This encompasses drugs for urinary tract infections, erectile dysfunction, urinary incontinence, overactive bladder, and other related conditions. The necessity of this market is underscored by the rising prevalence of genitourinary disorders due to factors such as aging populations and lifestyle changes. The application of these drugs spans across various healthcare settings, including hospitals, clinics, and homecare, with targeted end-users being patients requiring both acute and chronic treatment solutions. Key growth influencers include advances in biotechnology and pharmaceuticals, which facilitate the development of more effective and targeted therapies, improved diagnostic tools enhancing early detection, and growing healthcare expenditure.

KEY MARKET STATISTICS
Base Year [2023] USD 38.30 billion
Estimated Year [2024] USD 39.83 billion
Forecast Year [2030] USD 51.01 billion
CAGR (%) 4.17%

Recent opportunities in the market emerge from the increasing adoption of personalized medicine and biologics, which possess high therapeutic efficiency and fewer side effects. Leveraging these, companies can focus on developing drugs tailored to individual patient genetic profiles. Another promising area lies in digital therapeutics, integrating technology for enhanced patient adherence and monitoring, thereby improving treatment outcomes. Challenges limiting market expansion include stringent regulatory approvals that delay the introduction of new drugs, high R&D costs, and patent expirations leading to generic competition. Pricing pressures and reimbursement issues further compound market constraints as healthcare systems strive to control costs.

Innovation can pivot towards exploring novel drug delivery systems such as nanoparticles and sustained-release formulations, catering to patient compliance and enhancing drug efficacy. Additionally, targeting unmet needs in rare urological disorders could yield niche market growth opportunities. The market's nature is distinctly competitive and fast-evolving, driven by continuous research and development efforts. Strategic partnerships and collaborations could offer ways to consolidate resources and hasten new drug development. In conclusion, maintaining a clear focus on R&D, adaptation to regulatory updates, and responsiveness to technological advances are critical for sustained growth and competitive advantage in the genitourinary drugs market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Genitourinary Drugs Market

The Genitourinary Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of genitourinary disorders
    • Rising number of pipeline drugs
    • Growing concerns about urinary incontinence and impotence
  • Market Restraints
    • Availability of counterfeit and generics drugs in the market
  • Market Opportunities
    • Collaborative R&D efforts by the pharma companies
    • Growing investment in healthcare for improved treatments
  • Market Challenges
    • Lack of compliance to medication
    • Continual patent expirations

Porter's Five Forces: A Strategic Tool for Navigating the Genitourinary Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Genitourinary Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Genitourinary Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Genitourinary Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Genitourinary Drugs Market

A detailed market share analysis in the Genitourinary Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Genitourinary Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Genitourinary Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Genitourinary Drugs Market

A strategic analysis of the Genitourinary Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Genitourinary Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Asieris Pharmaceuticals, Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Cipla Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., and The Bristol Myers Squibb Company.

Market Segmentation & Coverage

This research report categorizes the Genitourinary Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Anti-infectives, Gynecological, Hormonal Therapy, and Urologicals.
  • Based on Indication, market is studied across Benign Prostatic Hyperplasia, Bladder Cancer, Cervical Cancer, Erectile Dysfunction, Hematuria, Interstitial Cystitis, Ovarian Cancer, Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Urinary Incontinence & Overactive Bladder, and Urinary Tract Infections.
  • Based on Drug Type, market is studied across Hormonal Therapy, Impotence Agents, Urinary Antispasmodics, Urinary pH Modifiers, Uterine Relaxants, and Uterine Stimulants.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of genitourinary disorders
      • 5.1.1.2. Rising number of pipeline drugs
      • 5.1.1.3. Growing concerns about urinary incontinence and impotence
    • 5.1.2. Restraints
      • 5.1.2.1. Availability of counterfeit and generics drugs in the market
    • 5.1.3. Opportunities
      • 5.1.3.1. Collaborative R&D efforts by the pharma companies
      • 5.1.3.2. Growing investment in healthcare for improved treatments
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of compliance to medication
      • 5.1.4.2. Continual patent expirations
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Genitourinary Drugs Market, by Product

  • 6.1. Introduction
  • 6.2. Anti-infectives
  • 6.3. Gynecological
  • 6.4. Hormonal Therapy
  • 6.5. Urologicals

7. Genitourinary Drugs Market, by Indication

  • 7.1. Introduction
  • 7.2. Benign Prostatic Hyperplasia
  • 7.3. Bladder Cancer
  • 7.4. Cervical Cancer
  • 7.5. Erectile Dysfunction
  • 7.6. Hematuria
  • 7.7. Interstitial Cystitis
  • 7.8. Ovarian Cancer
  • 7.9. Prostate Cancer
  • 7.10. Renal Cancer
  • 7.11. Sexually Transmitted Diseases
  • 7.12. Urinary Incontinence & Overactive Bladder
  • 7.13. Urinary Tract Infections

8. Genitourinary Drugs Market, by Drug Type

  • 8.1. Introduction
  • 8.2. Hormonal Therapy
  • 8.3. Impotence Agents
  • 8.4. Urinary Antispasmodics
  • 8.5. Urinary pH Modifiers
  • 8.6. Uterine Relaxants
  • 8.7. Uterine Stimulants

9. Americas Genitourinary Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Genitourinary Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Genitourinary Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. Asieris Pharmaceuticals
  • 4. Astellas Pharma Inc.
  • 5. AstraZeneca PLC
  • 6. Bayer AG
  • 7. Cipla Inc.
  • 8. Eli Lilly and Company
  • 9. F. Hoffmann-La Roche Ltd.
  • 10. GlaxoSmithKline PLC
  • 11. Johnson & Johnson Services, Inc.
  • 12. Merck & Co., Inc.
  • 13. Novartis AG
  • 14. Pfizer, Inc.
  • 15. Teva Pharmaceutical Industries Ltd.
  • 16. The Bristol Myers Squibb Company

LIST OF FIGURES

  • FIGURE 1. GENITOURINARY DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. GENITOURINARY DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GENITOURINARY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. GENITOURINARY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. GENITOURINARY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GENITOURINARY DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GENITOURINARY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GENITOURINARY DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ANTI-INFECTIVES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY GYNECOLOGICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY UROLOGICALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ERECTILE DYSFUNCTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY HEMATURIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INTERSTITIAL CYSTITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY RENAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY SEXUALLY TRANSMITTED DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY URINARY INCONTINENCE & OVERACTIVE BLADDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY IMPOTENCE AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY URINARY ANTISPASMODICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY URINARY PH MODIFIERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY UTERINE RELAXANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY UTERINE STIMULANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. MALAYSIA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. PHILIPPINES GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 75. PHILIPPINES GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. SINGAPORE GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 78. SINGAPORE GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. SINGAPORE GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. SOUTH KOREA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. SOUTH KOREA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 82. SOUTH KOREA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. TAIWAN GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 84. TAIWAN GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. TAIWAN GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. THAILAND GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 87. THAILAND GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. THAILAND GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. VIETNAM GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 90. VIETNAM GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. VIETNAM GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 96. DENMARK GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 97. DENMARK GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. DENMARK GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. EGYPT GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 100. EGYPT GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. EGYPT GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. FINLAND GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 103. FINLAND GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. FINLAND GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. FRANCE GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 106. FRANCE GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 107. FRANCE GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. GERMANY GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 109. GERMANY GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 110. GERMANY GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. ISRAEL GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 112. ISRAEL GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. ISRAEL GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. ITALY GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 115. ITALY GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. ITALY GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. NETHERLANDS GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 118. NETHERLANDS GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. NETHERLANDS GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. NIGERIA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 121. NIGERIA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 122. NIGERIA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. NORWAY GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 124. NORWAY GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. NORWAY GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. POLAND GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 127. POLAND GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 128. POLAND GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. QATAR GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 130. QATAR GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. QATAR GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. RUSSIA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 133. RUSSIA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 134. RUSSIA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SAUDI ARABIA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 136. SAUDI ARABIA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. SAUDI ARABIA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. SOUTH AFRICA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 139. SOUTH AFRICA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 140. SOUTH AFRICA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. SPAIN GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 142. SPAIN GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 143. SPAIN GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. SWEDEN GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 145. SWEDEN GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 146. SWEDEN GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. SWITZERLAND GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 148. SWITZERLAND GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 149. SWITZERLAND GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. TURKEY GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 151. TURKEY GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 152. TURKEY GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. UNITED ARAB EMIRATES GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 154. UNITED ARAB EMIRATES GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 155. UNITED ARAB EMIRATES GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. UNITED KINGDOM GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 157. UNITED KINGDOM GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 158. UNITED KINGDOM GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. GENITOURINARY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 160. GENITOURINARY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023